Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sirolimus
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LAM-001 (sirolimus) is a proprietary, investigational, inhaled formulation of sirolimus, which is investigated in Patients With pulmonary arterial hypertension.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
August 31, 2023
Lead Product(s) : Sirolimus
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sirolimus
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LAM-001 (sirolimus) is a proprietary, investigational, inhaled formulation of sirolimus, which is investigated in Patients With Bronchiolitis Obliterans Syndrome (BOS) Post-Lung Transplant.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
August 18, 2023
Lead Product(s) : Sirolimus
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apilimod mesylate
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AIT-101 (apilimod dimesylate) is a potent and highly selective inhibitor of the lipid kinase PIKfyve, which activates the transcription factor TFEB which drives the increased clearance of toxic protein aggregates. It is being investegated for treating C9...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 04, 2023
Lead Product(s) : Apilimod mesylate
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AIT-102
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : EntreChem
Deal Size : Undisclosed
Deal Type : Acquisition
AI Therapeutics Announces the Acquisition of Novel Cancer Drug Candidate EC-8042 (AIT-102)
Details : EC-8042 (redesignated AIT-102), is a targeted cancer therapy that inhibits the activity of SWI/SNF in certain tumors where SWI/SNF is mutated (such as Rhabdoid tumors) and in other tumors where SWI/SNF associates with oncogenic transcription factors.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
April 25, 2022
Lead Product(s) : AIT-102
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : EntreChem
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Apilimod mesylate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The randomized, double-blind, placebo-controlled study will enroll up to 142 outpatients to evaluate the safety, tolerability, and efficacy of LAM-002A in reducing viral load in subjects with a confirmed COVID-19.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 27, 2020
Lead Product(s) : Apilimod mesylate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sirolimus
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AI Therapeutics Announces Significant Progress on LAM-001 and LAM-004 Programs
Details : The company has made significant recent progress on its four clinical assets and proprietary Guardian Angel™ algorithm.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 01, 2020
Lead Product(s) : Sirolimus
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable